OTCMKTS:OSIR - Osiris Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.94 +0.38 (+3.03 %)
(As of 12/19/2018 08:18 AM ET)
Previous Close$12.56
Today's Range$12.57 - $13.25
52-Week Range$5.62 - $14.35
Volume127,228 shs
Average Volume46,191 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:OSIR
Previous SymbolNASDAQ:OSIR
CUSIP68827R10
Phone443-545-1800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees350
Outstanding Shares34,530,000
Market Cap$0.00
OptionableOptionable

Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

How were Osiris Therapeutics' earnings last quarter?

Osiris Therapeutics, Inc. (OTCMKTS:OSIR) issued its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported $0.11 earnings per share for the quarter. The biotechnology company earned $36.49 million during the quarter. View Osiris Therapeutics' Earnings History.

Has Osiris Therapeutics been receiving favorable news coverage?

Media stories about OSIR stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Osiris Therapeutics earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Osiris Therapeutics' key competitors?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:
  • Mr. Jason Keefer, Interim Pres & CEO (Age 46)
  • Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)
  • Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)
  • Mr. Edward Yip, Chief Legal Officer & Corp. Sec.
  • Mr. Laine Dyess, VP of Sales

Who are Osiris Therapeutics' major shareholders?

Osiris Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.07%), Vanguard Group Inc (2.07%), The Manufacturers Life Insurance Company (1.86%), Gabelli Funds LLC (1.33%), Gamco Investors INC. ET AL (0.20%) and B. Riley Financial Inc. (0.15%). View Institutional Ownership Trends for Osiris Therapeutics.

Which institutional investors are buying Osiris Therapeutics stock?

OSIR stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., The Manufacturers Life Insurance Company , Gabelli Funds LLC, Gamco Investors INC. ET AL, B. Riley Financial Inc., Deltec Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Osiris Therapeutics.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of OSIR stock can currently be purchased for approximately $12.94.

What is Osiris Therapeutics' official website?

The official website for Osiris Therapeutics is http://www.osiristx.com.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]


MarketBeat Community Rating for Osiris Therapeutics (OTCMKTS OSIR)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Featured Article: What is the quiet period?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel